-
1
-
-
67149138180
-
Rheumatic manifestations associated with HIV in the highly active antiretroviral therapy era
-
Nguyen BY, Reveille JD. Rheumatic manifestations associated with HIV in the highly active antiretroviral therapy era. Curr Opin Rheumatol 2009; 21: 404-10.
-
(2009)
Curr Opin Rheumatol
, vol.21
, pp. 404-410
-
-
Nguyen, B.Y.1
Reveille, J.D.2
-
3
-
-
49849103584
-
Severe rhabdomyolysis associated with raltegravir use
-
Zembower TR, Gerzenshtein L, Coleman K et al. Severe rhabdomyolysis associated with raltegravir use. AIDS 2008; 22: 1382-4.
-
(2008)
AIDS
, vol.22
, pp. 1382-1384
-
-
Zembower, T.R.1
Gerzenshtein, L.2
Coleman, K.3
-
4
-
-
75649112262
-
A case of rhabdomyolysis associated with raltegravir use
-
Dori L, Buonomini AR, Viscione M et al. A case of rhabdomyolysis associated with raltegravir use. AIDS 2010; 24: 473-5.
-
(2010)
AIDS
, vol.24
, pp. 473-475
-
-
Dori, L.1
Buonomini, A.R.2
Viscione, M.3
-
5
-
-
77955049938
-
Severe acute renal failure associated with rhabdomyolysis during treatment with raltegravir. A call for caution
-
Masiá M, Enríquez R, Sirvent A et al. Severe acute renal failure associated with rhabdomyolysis during treatment with raltegravir. A call for caution. J Infect 2010; 61: 189-90.
-
(2010)
J Infect
, vol.61
, pp. 189-190
-
-
Masiá, M.1
Enríquez, R.2
Sirvent, A.3
-
6
-
-
78650825831
-
Severe raltegravir-associated rhabdomyolysis: a case report and review of the literature
-
Croce F, Vitello P, Dalla Pria A et al. Severe raltegravir-associated rhabdomyolysis: a case report and review of the literature. Int J STD AIDS 2010; 21: 783-5.
-
(2010)
Int J STD AIDS
, vol.21
, pp. 783-785
-
-
Croce, F.1
Vitello, P.2
Dalla Pria, A.3
-
7
-
-
84857239027
-
-
Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. (27 June, date last accessed)
-
Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. http:// www.aidsinfo.nih.gov/ContentFiles/vguidelines/AdultandAdolescentGL. pdf (27 June 2012, date last accessed).
-
(2012)
Panel on Antiretroviral Guidelines for Adults and, Adolescents
-
-
-
8
-
-
44949194170
-
-
European AIDS Clinical Society (EACS). Version 6.0 (October 2011). (27 June date last accessed)
-
European AIDS Clinical Society (EACS). Guidelines for clinical management and treatment of HIV-infected adults in Europe. Version 6.0 (October 2011). http://www.europeanaidsclinicalsociety.org/images/stories/ EACS-Pdf/EACSguidelines-v6.0-English.pdf (27 June 2012, date last accessed).
-
(2012)
Guidelines for clinical management and treatment of HIV-infected adults in Europe
-
-
-
9
-
-
77954348583
-
Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study
-
Martínez E, Larrousse M, Llibre JM et al. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. AIDS 2010; 24: 1697-707.
-
(2010)
AIDS
, vol.24
, pp. 1697-1707
-
-
Martínez, E.1
Larrousse, M.2
Llibre, J.M.3
-
10
-
-
63649087422
-
Raltegravir: the first HIV type 1 integrase inhibitor
-
Hicks C, Gulick RM. Raltegravir: the first HIV type 1 integrase inhibitor. Clin Infect Dis 2009; 48: 931-9.
-
(2009)
Clin Infect Dis
, vol.48
, pp. 931-939
-
-
Hicks, C.1
Gulick, R.M.2
-
11
-
-
84896503763
-
Role of raltegravir in the management of HIV-1 infection
-
Okeke NL, Hicks C. Role of raltegravir in the management of HIV-1 infection. HIV AIDS 2011; 3: 81-92.
-
(2011)
HIV AIDS
, vol.3
, pp. 81-92
-
-
Okeke, N.L.1
Hicks, C.2
-
12
-
-
80052905594
-
Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK
-
Rockstroh JK, Lennox JL, Dejesus E et al. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Clin Infect Dis 2011; 53: 807-16.
-
(2011)
Clin Infect Dis
, vol.53
, pp. 807-816
-
-
Rockstroh, J.K.1
Lennox, J.L.2
Dejesus, E.3
-
13
-
-
84865623088
-
Tolerability of integrase inhibitors
-
Lee FJ, Carr A. Tolerability of integrase inhibitors. Curr Opin HIV AIDS 2012; 7: 422-8.
-
(2012)
Curr Opin HIV AIDS
, vol.7
, pp. 422-428
-
-
Lee, F.J.1
Carr, A.2
-
14
-
-
2542496096
-
Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count
-
García F, de Lazzari E, Plana M et al. Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count. J Acquir Immune Defic Syndr 2004; 36: 702-13.
-
(2004)
J Acquir Immune Defic Syndr
, vol.36
, pp. 702-713
-
-
García, F.1
de Lazzari, E.2
Plana, M.3
-
15
-
-
33644960500
-
Antiretroviral therapy of HIV infection: duration and reasons for changing the first therapeutic regimen in 518 patients
-
Gratacòs L, Tuset M, Codina C et al. Antiretroviral therapy of HIV infection: duration and reasons for changing the first therapeutic regimen in 518 patients. Med Clin 2006; 126: 241-5.
-
(2006)
Med Clin
, vol.126
, pp. 241-245
-
-
Gratacòs, L.1
Tuset, M.2
Codina, C.3
-
16
-
-
34247850998
-
Incidence and causes of death in HIV-infected persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar age and from the same geographical area
-
Martínez E, Milinkovic A, Buira E et al. Incidence and causes of death in HIV-infected persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar age and from the same geographical area. HIV Med 2007; 8: 251-8.
-
(2007)
HIV Med
, vol.8
, pp. 251-258
-
-
Martínez, E.1
Milinkovic, A.2
Buira, E.3
-
17
-
-
47949120697
-
Raltegravir with optimized background therapy for resistant HIV-1 infection
-
Steigbigel RT, Cooper DA, Kumar PN et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359: 339-54.
-
(2008)
N Engl J Med
, vol.359
, pp. 339-354
-
-
Steigbigel, R.T.1
Cooper, D.A.2
Kumar, P.N.3
-
18
-
-
75749107023
-
Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials
-
Steigbigel RT, Cooper DA, Teppler H et al. Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis 2010; 50: 605-12.
-
(2010)
Clin Infect Dis
, vol.50
, pp. 605-612
-
-
Steigbigel, R.T.1
Cooper, D.A.2
Teppler, H.3
-
19
-
-
77949381837
-
Long term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a phase II study
-
Gatell JM, Katlama C, Grinzstejn B et al. Long term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a phase II study. J Acquir Immune Defic Syndr 2010; 53: 456-63.
-
(2010)
J Acquir Immune Defic Syndr
, vol.53
, pp. 456-463
-
-
Gatell, J.M.1
Katlama, C.2
Grinzstejn, B.3
-
20
-
-
70350558421
-
Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection
-
Markowitz M, Nguyen BY, Gotuzzo E et al. Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection. J Acquir Immune Defic Syndr 2009; 52: 350-6.
-
(2009)
J Acquir Immune Defic Syndr
, vol.52
, pp. 350-356
-
-
Markowitz, M.1
Nguyen, B.Y.2
Gotuzzo, E.3
-
21
-
-
81855166275
-
Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomized, active-controlled, phase 3 non-inferiority trial
-
Eron JJ Jr, Rockstroh JK, Reynes J et al. Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomized, active-controlled, phase 3 non-inferiority trial. Lancet Infect Dis 2011; 11: 907-15.
-
(2011)
Lancet Infect Dis
, vol.11
, pp. 907-915
-
-
Eron Jr., J.J.1
Rockstroh, J.K.2
Reynes, J.3
-
22
-
-
84255190565
-
Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results
-
Reynes J, Lawal A, Pulido F et al. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results. HIV Clin Trials 2011; 12: 255-67.
-
(2011)
HIV Clin Trials
, vol.12
, pp. 255-267
-
-
Reynes, J.1
Lawal, A.2
Pulido, F.3
-
23
-
-
79251630271
-
A pilot study of abacavir/lamivudine and raltegravir in antiretroviral-naïve HIV-1-infected patients: 48-week results of the SHIELD trial
-
Young B, Vanig T, Dejesus E et al. A pilot study of abacavir/lamivudine and raltegravir in antiretroviral-naïve HIV-1-infected patients: 48-week results of the SHIELD trial. HIV Clin Trials 2010; 11: 260-9.
-
(2010)
HIV Clin Trials
, vol.11
, pp. 260-269
-
-
Young, B.1
Vanig, T.2
Dejesus, E.3
-
24
-
-
72849119170
-
High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrugresistant HIV: results of the ANRS 139 TRIO trial
-
Yazdanpanah Y, Fagard C, Descamps D et al. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrugresistant HIV: results of the ANRS 139 TRIO trial. Clin Infect Dis 2009; 49: 1441-9.
-
(2009)
Clin Infect Dis
, vol.49
, pp. 1441-1449
-
-
Yazdanpanah, Y.1
Fagard, C.2
Descamps, D.3
-
25
-
-
80051693755
-
Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial
-
Gallien S, Braun J, Delaugerre C et al. Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial. J Antimicrob Chemother 2011; 66: 2099-106.
-
(2011)
J Antimicrob Chemother
, vol.66
, pp. 2099-2106
-
-
Gallien, S.1
Braun, J.2
Delaugerre, C.3
-
26
-
-
84872422631
-
Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: results from a multicenter study
-
Abstract P111, International AIDS Society, Geneva, Switzerland, Glasgow, UK
-
Madeddu G, Soddu V, Ricci E et al. Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: results from a multicenter study. In: Abstracts of the Tenth International Congress on Drug Therapy in HIV Infection, Glasgow, UK, 2010. Abstract P111, p. 71. International AIDS Society, Geneva, Switzerland.
-
(2010)
Abstracts of the Tenth International Congress on Drug Therapy in HIV Infection
, pp. 71
-
-
Madeddu, G.1
Soddu, V.2
Ricci, E.3
-
27
-
-
77956646683
-
Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses
-
Lennox JL, Dejesus E, Berger DS et al. Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr 2010; 55: 39-48.
-
(2010)
J Acquir Immune Defic Syndr
, vol.55
, pp. 39-48
-
-
Lennox, J.L.1
Dejesus, E.2
Berger, D.S.3
-
28
-
-
77954257512
-
Raltegravir: the evidence of its therapeutic value in HIV-1 infection
-
Ramkumar K, Neamati N. Raltegravir: the evidence of its therapeutic value in HIV-1 infection. Core Evid 2010; 4: 131-47.
-
(2010)
Core Evid
, vol.4
, pp. 131-147
-
-
Ramkumar, K.1
Neamati, N.2
|